Sandoz’s 2017 Trifecta in Biosimilar Battle with Amgen
14 the Biologics Price Competition and Innovation Act preempts state law and prevents biologic reference product holders like Amgen from relying on state remedies to force biosimilar applicants to participate in the BPCIA’s information disclosure “patent dance.” Amgen had argued Sandoz violated …